<DOC>
	<DOCNO>NCT02189161</DOCNO>
	<brief_summary>Assess safety , feasibility , patient tolerability circumferential radiofrequency ablation ( RFA ) anal canal patient anal intraepithelial neoplasia ( AIN ) . Patients AIN high grade squamous intraepithelial lesion ( HSIL ) RFA apply use Barrx™ Ablation System .</brief_summary>
	<brief_title>A Safety Tolerability Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Squamous Intraepithelial Lesions Cervix</mesh_term>
	<criteria>Inclusion Criteria Candidates study must meet following criterion : 1 . Age 1875 year 2 . HRA 2 8 week prior 0 month RFA visit yield one flat , noncondylomatous biopsyproven HSILs Located entirely within eligible treatment zone AND Contiguous squamocolumnar junction 3 . Eligible treatment zone ( ETZ ) define 3 cm dentate line anocutaneous line AND Full anorectal circumference 4 . If female childbearing age , negative pregnancy test within 8 week 0 month RFA visit declare intent remain birth control throughout trial , declaration infertility define subject report status postmenopausal surgically sterile ( status post hysterectomy tubal ligation ) . 5 . If HIV positive HIV positive antiretroviral therapy least 3 month laboratory blood work within 12 week prior 0 month visit demonstrate viral load &lt; 50 CD4 count ≥ 250/mm3 ANC &gt; 750/mm3 Platelet count ≥ 75,000/mm3 Hemoglobin ≥ 9.0 g/dl INR PTT normal Exclusion Criteria Candidates ineligible enrollment study follow condition apply : 1 . Any biopsyproven HSIL partially outside ETZ ( example , HSIL lesion extension perianal skin ) 2 . Any condylomas eligible treatment zone &gt; 1/2 cm diameter • Note : Condylomas eligible treatment zone &lt; 1/2 cm diameter must excise cauterize ( treat topically ) Visit 1 ( 0 month RFA visit ) 3 . Any anal rectal pathology require treatment include ulcer , fistula , fissure , proctitis 4 . Any anal stricture stenosis patient history upon examination . 5 . Symptomatic scar anal canal ( i.e . pliable , hyperkeratosis ) 6 . History present anal rectal cancer 7 . History pelvic radiation therapy 8 . History HPV vaccination plan initiate HPV vaccination trial 9 . History ablation resection therapy within ETZ within 6 month prior 0 month RFA visit ( cauterization excision condyloma ( ) ) 10 . Prior ablation resection therapy consist ≥ 75 % circumference within ETZ anal canal . 11 . History topical therapy ( e.g . Imiquimod , 5FU , Trichloroacetic acid ) within ETZ within 3 month prior 0 month RFA visit 12 . Hemorrhoids &gt; grade III 13 . Fecal incontinence 14 . Concurrent disease require systemic immunosuppression therapy 15 . Concurrent malignancy require systemic therapy 16 . Life expectancy &lt; 2 year 17 . Subject platelet inhibiting agent ( i.e . Aspirin , Clopidogrel , NSAIDS ) and/or antithrombotic agent ( Heparin , Warfarin ) unable discontinue 7 day treatment 14 day total . Exception : Aspirin 81 mg PO daily need discontinue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>anal intraepithelial neoplasia</keyword>
	<keyword>AIN</keyword>
	<keyword>Radiofrequency Ablation</keyword>
	<keyword>RFA</keyword>
</DOC>